Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- US stock futures rise as oil pullback amplifies Fed rate-hike boost
- Oil falls 3% to one-week low as supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Turkish Stocks Fall 6%, Triggering Market-wide Circuit Breaker - Bloomberg
Kala Pharmaceuticals (KALA) Tops Q1 EPS by 19c, Revenues Miss
May 5, 2021 7:23 AM EDTKala Pharmaceuticals (NASDAQ: KALA) reported Q1 EPS of ($0.49), $0.19 better than the analyst estimate of ($0.68). Revenue for the quarter came in at $3.27 million versus the consensus estimate of $4.18 million.
We are early in the launch of EYSUVIS and encouraged by our progress... More
